
LYNPARZA® (olaparib) Demonstrated Overall Survival Benefit in Phase 3 PROfound Trial for BRCA1/2 or ATM-Mutated Metastatic Castration-Resistant Prostate Cancer
Dateline City: KENILWORTH, N.J. Only PARP Inhibitor to Improve Overall Survival vs. New Hormonal Agent…







.jpg)












.jpg)


